Veru Beheer

Beheer criteriumcontroles 3/4

De CEO Veru is Mitch Steiner, benoemd in Oct2016, heeft een ambtstermijn van 8.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 4.71M, bestaande uit 18.4% salaris en 81.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 4.84% van de aandelen van het bedrijf, ter waarde € 4.78M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.3 jaar en 4 jaar.

Belangrijke informatie

Mitch Steiner

Algemeen directeur

US$4.7m

Totale compensatie

Percentage CEO-salaris	18.4%
Dienstverband CEO	8.2yrs
Eigendom CEO	4.8%
Management gemiddelde ambtstermijn	6.3yrs
Gemiddelde ambtstermijn bestuur	4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Mitch Steiner's beloning veranderd ten opzichte van Veru's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$37m
Mar 31 2024	n/a	n/a	-US$39m
Dec 31 2023	n/a	n/a	-US$63m
Sep 30 2023	US$5m	US$866k	-US$93m
Jun 30 2023	n/a	n/a	-US$126m
Mar 31 2023	n/a	n/a	-US$136m
Dec 31 2022	n/a	n/a	-US$116m
Sep 30 2022	US$6m	US$761k	-US$84m
Jun 30 2022	n/a	n/a	-US$47m
Mar 31 2022	n/a	n/a	-US$28m
Dec 31 2021	n/a	n/a	-US$16m
Sep 30 2021	US$2m	US$618k	US$7m
Jun 30 2021	n/a	n/a	-US$144k
Mar 31 2021	n/a	n/a	-US$476k
Dec 31 2020	n/a	n/a	US$2m
Sep 30 2020	US$1m	US$502k	-US$19m
Jun 30 2020	n/a	n/a	-US$10m
Mar 31 2020	n/a	n/a	-US$10m
Dec 31 2019	n/a	n/a	-US$13m
Sep 30 2019	US$800k	US$392k	-US$12m
Jun 30 2019	n/a	n/a	-US$17m
Mar 31 2019	n/a	n/a	-US$22m
Dec 31 2018	n/a	n/a	-US$22m
Sep 30 2018	US$740k	US$383k	-US$24m

Compensatie versus markt: De totale vergoeding ($USD 4.71M ) Mitch } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 475.17K ).

Compensatie versus inkomsten: De vergoeding van Mitch is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Mitch Steiner (63 yo)

8.2yrs

Tenure

US$4,714,041

Compensatie

Dr. Mitchell S. Steiner, also known as Mitch, M.D., F.A.C.S, has been the Chief Executive Officer, President and Director at Veru Inc. (formerly known as The Female Health Company) since October 31, 2016 &...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Mitchell Steiner	Chairman	8.2yrs	US$4.71m	4.84% € 4.8m
Harry Fisch	Vice Chairman & Chief Corporate Officer	8.2yrs	geen gegevens	5.47% € 5.4m
Michele Greco	CFO & Chief Administrative Officer	7yrs	US$1.55m	0.066% € 64.9k
K. Barnette	Chief Scientific Officer	6.3yrs	US$1.69m	0.0034% € 3.4k
Samuel Fisch	Executive Director of Investor Relations & Corporate Communications	5.7yrs	geen gegevens	geen gegevens
Michael Purvis	Executive VP	3.8yrs	geen gegevens	geen gegevens
Kevin Gilbert	Executive Vice President of Corporate Development	7.9yrs	geen gegevens	geen gegevens
Martin Tayler	Executive Vice President of FC2 Global Operations	no data	US$193.01k	geen gegevens
Philip Greenberg	Executive VP & Deputy General Counsel	3.9yrs	geen gegevens	geen gegevens
Domingo Rodriguez	Executive Vice President of Global Clinical Operations	6.7yrs	geen gegevens	geen gegevens
Gary Bird	Executive Vice President of Quality & Regulatory Affairs	5.8yrs	geen gegevens	geen gegevens
Jason Davies	Executive VP and GM of UK	2.3yrs	geen gegevens	geen gegevens

6.3yrs

Gemiddelde duur

62.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van FMW is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Mitchell Steiner	Chairman	8.2yrs	US$4.71m	4.84% € 4.8m
Harry Fisch	Vice Chairman & Chief Corporate Officer	8.2yrs	geen gegevens	5.47% € 5.4m
Louis Aronne	Chief Medical Advisor & Member of the Scientific Advisory	less than a year	geen gegevens	geen gegevens
David D. Ho	Chairman of Scientific Advisory Board	1.9yrs	geen gegevens	geen gegevens
Andrew Love	Board Observer	8.2yrs	geen gegevens	geen gegevens
Robert Schooley	Member of the Scientific Advisory Board	1.5yrs	geen gegevens	geen gegevens
Michael Rankowitz	Independent Director	6.8yrs	US$875.93k	0.068% € 67.5k
Xiaoqin Lu	Independent Director	3.6yrs	US$835.75k	0.0067% € 6.6k
Caroline Apovian	Member of Scientific Advisory Board	less than a year	geen gegevens	geen gegevens
Mario Eisenberger	Independent Director	8.2yrs	US$795.57k	0% € 0
Grace Hyun	Independent Director	4.3yrs	US$755.39k	0.010% € 10.0k
Erik Swenson	Member of the Scientific Advisory Board	1.5yrs	geen gegevens	geen gegevens

4.0yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van FMW wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).

Veru Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Chairman recently sold €227k worth of stock

High number of new and inexperienced directors

Veru Inc. Appoints Louis Aronne as Chief Medical Advisor and A Member of the Scientific Advisory Board

Veru Inc. Announces New Scientific Advisory Board for Its Enobosarm Program for High Quality Weight Loss

Veru Inc., Annual General Meeting, Mar 26, 2024

High number of new and inexperienced directors

Recent updates

New minor risk - Market cap size

Veru Inc. Announces Meta-Analysis of Body Composition Data from Older Patients with Obesity Which Supports Potential for Enobosarm to Optimize Weight Loss At Obesityweek

Veru Receives Notification from The Nasdaq Stock Market

Third quarter 2024 earnings released: US$0.075 loss per share (vs US$0.075 loss in 3Q 2023)

Veru Inc. to Report Q3, 2024 Results on Aug 08, 2024

New major risk - Financial position

Veru Inc. to Present an Update of Veru's Phase 2B Clinical Program of Enobosarm to Augment Fat Loss and to Avoid Muscle Loss When Combined with GLP-1 Drugs for Weight Loss At the Jefferies Global Healthcare Conference

Chairman recently sold €227k worth of stock

High number of new and inexperienced directors

Veru Inc. to Report Q2, 2024 Results on May 08, 2024

Veru Inc. Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Veru Inc. Appoints Louis Aronne as Chief Medical Advisor and A Member of the Scientific Advisory Board

Veru Receives a Notification Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Veru Inc. Announces New Scientific Advisory Board for Its Enobosarm Program for High Quality Weight Loss

Veru Inc. announced delayed 10-Q filing

Veru Inc. Announces U.S. Food and Drug Administration Clearance of Investigational New Drug Application for its Phase 2b Clinical Study

Veru Receives Non-Compliance Notice From Nasdaq

Veru Inc., Annual General Meeting, Mar 26, 2024

Veru Inc. to Report Q1, 2024 Results on Feb 08, 2024

Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with Glp-1 Drugs for Weight Loss

New major risk - Shareholder dilution

Veru Inc. has completed a Follow-on Equity Offering in the amount of $33 million.

Veru Inc. has completed a Follow-on Equity Offering in the amount of $33 million.

Third quarter 2023 earnings released: US$0.075 loss per share (vs US$0.28 loss in 3Q 2022)

Veru Inc. Reports Muscle Data from 5 Clinical Studies of Enobosarm

Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication

Veru Inc. Announces Clinical Data from Its Discontinued Phase 3 ARTEST Clinical Trial of Enobosarm Monotherapy

New major risk - Financial position

Third quarter 2023 earnings released: EPS: US$0.072 (vs US$0.28 loss in 3Q 2022)

New minor risk - Market cap size

Veru Inc. to Report Q3, 2023 Results on Aug 10, 2023

High number of new and inexperienced directors

Veru Inc.(NasdaqCM:VERU) dropped from Russell 2000 Dynamic Index

Veru Announces Executive Appointments

Second quarter 2023 earnings released: US$0.48 loss per share (vs US$0.18 loss in 2Q 2022)

Veru Inc. announced that it expects to receive $100 million in funding from Lincoln Park Capital, LLC

Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS

First quarter 2023 earnings released: US$0.46 loss per share (vs US$0.08 loss in 1Q 2022)

Veru Inc., Annual General Meeting, Mar 28, 2023

Veru Inc. to Report Q1, 2023 Results on Feb 09, 2023

Bragar Eagel & Squire, P.C. Announces Class Action Lawsuit Against Veru Inc

Veru Inc. Appoints David D. Ho as Chairman of Its Scientific Advisory Board

Wolf Haldenstein Adler Freeman & Herz LLP Announces Securities Class Action Lawsuit Against Veru Inc

Full year 2022 earnings released: US$1.05 loss per share (vs US$0.097 profit in FY 2021)

Veru Inc. Provides Update on FDA Advisory Committee Meeting Regarding Emergency Use Authorization of Sabizabulin to Treat Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

Veru Inc. Announces Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with Covid-19 on Supplemental Oxygen At Infectious Disease Week 2022

Veru Inc. to Present Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with Covid-19 on Supplemental Oxygen At Infectious Disease Week 2022

Veru Inc. Receives Expedited Provisional Registration Regulatory Pathway for Sabizabulin Treatment in Hospitalized COVID-19 Patients by Australia’s Therapeutic Goods Administration

Veru Inc. Appoints Jason Davies as Executive Vice President General Manager of Europe, the Middle East and Africa, Latin America, and Asia Pacific

Third quarter 2022 earnings released: US$0.28 loss per share (vs US$0.034 loss in 3Q 2021)

Veru Inc. to Report Q3, 2022 Results on Aug 11, 2022

Uk’S Medicines and Healthcare Products Regulatory Agency (Mhra) Supports Expedited Review of Marketing Authorization Application for Sabizabulin Treatment in Hospitalized Covid-19 Patients of Veru Inc

Veru Announces New England Journal of Medicine Evidence Publication of Phase 3 Clinical Trial Results Demonstrating That Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized Covid-19 Patients

Veru Submits Emergency Use Authorization Application to U.S. FDA for Sabizabulin, Its Novel, Oral Antiviral and Anti-Inflammatory Drug Candidate for Hospitalized COVID-19 Patients At High Risk for ARDS

Veru Announces Presentation of Final Positive Phase 1b/2 Clinical Trial Results for Sabizabulin in Metastatic Castration Resistant Prostate Cancer at the 2022 American Society of Clinical Oncology Annual Meeting

Veru Inc. Appoints Joel Batten as Executive Vice President and Head of Its U.S. Infectious Disease Franchise, Effective May 23, 2022

Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.038 loss in 2Q 2021)

FDA Has Grants Veru Inc.'s Pre-Emergency Use Authorization (EUA) Meeting Date for Positive Sabizabulin Phase 3 COVID-19 Study

Veru Inc. Announces Results from Randomized Placebo-Controlled Phase 2 Study of Oral Sabizabulin

Veru Inc.'s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study

Veru Inc. Announces the Presentation of Updated Data from the Phase 1B/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer At the 2022 ASCO Genitourinary Cancers Symposium

Veru Inc. Reports That Independent Data Monitoring Committee for the Phase 3 Sabizabulin COVID-19 Clinical Study Recommends Continuing Study as Planned

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Investor sentiment improved over the past week

Veru Inc. Announces FDA Grant of Fast Track Designation for Sabizabulin for the Treatment of Hospitalized COVID-19 Patients At High Risk for Acute Respiratory Distress Syndrome

Veru Inc., Annual General Meeting, Mar 29, 2022

Veru Inc., Annual General Meeting, Mar 29, 2022

Investor sentiment improved over the past week

Veru Inc. Announces FDA Grant of Fast Track Designation for Enobosarm for the Treatment of AR+ ER+ HER2- Metastatic Breast Cancer